<DOC>
	<DOCNO>NCT02819557</DOCNO>
	<brief_summary>This Phase 2 , multiple-dose , open-label study evaluate safety , pharmacokinetics ( PK ) ataluren patient age ≥2 &lt; 5 year old Duchenne muscular dystrophy cause nonsense mutation dystrophin gene . The study include 4-week screening period , 4-week study period , 48-week extension period patient complete 4-week study period ( 52 week total treatment ) .</brief_summary>
	<brief_title>Study Ataluren ≥2 &lt; 5 Year-Old Males With Duchenne Muscular Dystrophy</brief_title>
	<detailed_description />
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<criteria>Males ≥2 &lt; 5 year age Body weight ≥12 kg Diagnosis DMD Nonsense mutation least 1 allele dystrophin gene Participation drug device clinical investigation Ongoing use prohibit concomitant medication</criteria>
	<gender>Male</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>